Team-based primary care is needed now more than ever as our “on-demand” and mobile lives, complicated by a primary care shortage crisis, have led to a more transactional and fragmented healthcare experience.
Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers. It’s the third indication for the drug, which analysts project could top $4 billion in peak sales.
We must advocate for the positive impact that technology can have on healthcare outcomes, while also building solutions to create a more equitable health system. This includes traditional, less tech-reliant methods for those unable to embrace technology.
Luna an at-home physical therapy provider released a new study on the efficacy of its post-surgery rehabilitation program. The study, which was conducted by the startup, showed that the Luna Pathways program did a good job of reducing patients’ pain, increasing care plan adherence, and decreasing avoidable hospital readmissions and emergency department visits.
The Apellis Pharmaceuticals restructuring will save up to $300 million. It comes as the biotech continues its inquiry into the cause of a rare inflammatory complication reported in a small number of patients who received its geographic atrophy drug, Syfovre.